Roche Holding AG Expands U.S. Manufacturing and Raises Capital
Roche Holding AG has announced a $750 million investment in a new fill‑finish facility for its U.S. subsidiary Genentech. The expansion will double the capacity of the company’s existing manufacturing plant in Hillsboro, Oregon, and will include the assembly of injectable medicines and delivery devices. The facility is expected to strengthen Roche’s end‑to‑end U.S. drug‑manufacturing capabilities and support the production of a broad portfolio of pharmaceuticals, including oncology, cardiovascular, and metabolic products.
The investment is part of Roche’s ongoing strategy to enhance its manufacturing footprint in the United States. Genentech’s announcement, made on 20 August 2026, was corroborated by multiple news outlets, including FiercePharma, Seeking Alpha, and Globe Newswire. The expansion is scheduled to be completed in phases, with the first phase targeting increased capacity for existing drug candidates and the second phase focused on future biologic therapies.
In addition to the manufacturing expansion, Roche Holding AG has issued a new capital‑market bond. The bond, with ISIN CH1593191XXX (WKN A4EZDZ), totals CHF 410 million and will mature in 2036. The bond was announced by the Börse Stuttgart on 18 August 2026 and is part of Roche’s broader capital‑raising effort to fund research and development, acquisitions, and global expansion initiatives.
Roche’s share price has experienced volatility amid the announcements. As of 19 August 2026, the stock closed at CHF 376. The 52‑week high reached CHF 383 on 23 February 2026, while the 52‑week low was CHF 264.6 on 28 September 2025. The price‑earnings ratio stands at 24.22, reflecting investor expectations of continued growth in the pharmaceutical sector.
The company’s market capitalization is CHF 366.63 billion, underscoring its status as a leading player in the global healthcare industry. Roche’s expansion in Oregon and the new bond issuance signal confidence in the company’s long‑term strategy to maintain a robust manufacturing presence in the United States while securing financial flexibility for future investments.
